Hirokazu Kanegane

Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis

Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, has demonstrated therapeutic potential in both primary and secondary hemophagocytic lymphohistiocytosis (pHLH & sHLH), but quantitative evidence comparing its efficacy and safety across subtypes remains lacking. Given the absence of rando...